Mira Pharmaceuticals Inc. has announced a definitive agreement to acquire SKNY Pharmaceuticals Inc., a biotechnology company specializing in therapies for obesity and nicotine dependence. The acquisition, unanimously approved by Mira's Board of Directors, follows independent valuations by Moore Financial Consulting, which valued SKNY at approximately $30.5 million and Mira at $30 million. As part of the transaction, SKNY will contribute $5 million in assets or cash to Mira upon closing. This strategic move is expected to bolster Mira's balance sheet and enhance its development initiatives, creating a combined enterprise with a value exceeding $60 million.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。